Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

BACKGROUND: Trastuzumab with cisplatin and fluoropyrimidine is the standard treatment in metastatic HER2-positive gastric or gastroesophageal (GE) junction adenocarcinoma, however there is limited data on the efficacy of trastuzumab in combination with a three-drug regimen in this setting. We examin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gastric Cancer
Autori principali: Mondaca, Sebastian, Margolis, Matthew, Sanchez-Vega, Francisco, Jonsson, Philip, Riches, Jamie C., Ku, Geoffrey Y., Hechtman, Jaclyn F., Tuvy, Yaelle, Berger, Michael F., Shah, Manish A., Kelsen, David P., Ilson, David H., Yu, Kenneth, Goldberg, Zoe, Epstein, Andrew S., Desai, Avni, Chung, Vincent, Chou, Joanne F., Capanu, Marinela, Solit, David B., Schultz, Nikolaus, Janjigian, Yelena Y.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784321/
https://ncbi.nlm.nih.gov/pubmed/30088161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-018-0861-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi